Cardiovascular diseases (CVDs) are pointed out by the World Health Organization (WHO)
as the leading cause of death, contributing to a significant and growing global health and …

Drug-induced cardiotoxicity (DICT) is a leading cause of drug trial failure and
discontinuation. Current drug annotations for cardiotoxicity largely focus on individual …

Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) have been reported to
exhibit immature embryonic or fetal cardiomyocyte-like phenotypes. To enhance the …

The prevalence of cardiovascular risk factors is expected to increase the occurrence of
cardiovascular diseases (CVDs) worldwide. Cardiac organoids are promising candidates for …

A series of structurally novel GluN2B NMDAR antagonists were designed, synthesized, and
biologically evaluated as anti-stroke therapeutics by optimizing the chemical structure of …

Oncotherapeutics research is progressing at a rapid pace, however, not many drugs
complete the successful clinical trial because of severe off-target toxicity to cardiomyocytes …

Recent advances in human induced pluripotent stem cell (hiPSC)-derived cardiac
microtissues provide a unique opportunity for cardiotoxic assessment of pharmaceutical and …

The identification of drug-induced cardiotoxicity remains a pressing challenge with far-
reaching clinical and economic ramifications, often leading to patient harm and resource …

The heart tissue is a potential target of various noxae contributing to the onset of
cardiovascular diseases. However, underlying pathophysiological mechanisms are largely …

Heart failure remains the world's leading cause of death worldwide, with limited treatment
options aside from palliation and a desperate need for effective preclinical models. The …